Hope Rugo, Professor of Medicine at the University of California San Francisco, shared a post on X:
“Great news for patients. Now we have to decide how to optimally use this combo! FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer! Maintenance and added value of P are key issues.
Kelly Shanahan, Director at METAvivor Research And Support, shared the above post, adding:
“It will be interesting to see the consensus on how to use TDXd + pertuzamab 1st line – how long should induction be, what should be maintenance (likely dependent on ER status, +/- brain mets, and ALWAYS what the patient wants, after true shared decision making discussion).”
Read the full news article: FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer.